Skip Navigation

This Article
Right arrow Abstract
Right arrow FREE Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content

Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy
Nucl. Acids Res. Albertini et al. 34: 1721

Supplementary Data

Files in this Data Supplement:



This Article
Right arrow Abstract
Right arrow FREE Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content